Market closed

Atea/$AVIR

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Atea

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Ticker

$AVIR

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Boston, United States

Employees

Website

ateapharma.com

Atea Metrics

BasicAdvanced

$266M

-

-$2.07

0.17 -

Price and volume

Market cap

$266M

Beta

0.17

52-week high

$4.60

52-week low

$2.75

Average daily volume

505K

Financial strength

Current ratio

19.329

Quick ratio

19.167

Long term debt to equity

0.228

Total debt to equity

0.4

Management effectiveness

Return on assets (TTM)

-14.25%

Return on equity (TTM)

-33.45%

Valuation

Price to book

0.58

Price to tangible book (TTM)

0.58

Price to free cash flow (TTM)

-2.085

Growth

Earnings per share change (TTM)

31.57%

3-year earnings per share growth (CAGR)

88.08%

What the Analysts think about Atea

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Atea stock.

Atea Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Atea Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Atea News

AllArticlesVideos

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·7 days ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Business Wire·4 weeks ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

GlobeNewsWire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVIR

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Atea stock?

Atea (AVIR) has a market cap of $266M as of January 15, 2025.

What is the P/E ratio for Atea stock?

The price to earnings (P/E) ratio for Atea (AVIR) stock is 0 as of January 15, 2025.

Does Atea stock pay dividends?

No, Atea (AVIR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Atea dividend payment date?

Atea (AVIR) stock does not pay dividends to its shareholders.

What is the beta indicator for Atea?

Atea (AVIR) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.